Marion Kiechle
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148:159-170.
Mar 18, 2021Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Mar 18, 2021Eur J Cancer 2021; 148:159-170
Villegas Sonia L, Huober Jens, Lederer Bianca, van Mackelenbergh Marion, Tesch Hans, Jackisch Christian, Rezai Mahdi, Sinn Peter, Sinn Bruno V, Hackmann John, Kiechle Marion, Schneeweiss Andreas, Weichert Wilko, Denkert Carsten, Schmitt Wolfgang D, Hanusch Claus, Nekljudova Valentina, Pfarr Nicole, Engel Jutta, Untch Michael, Schrodi Simone, Holms Frank, Ulmer Hans U, Fasching Peter A, Weber Karsten E, Albig Christian, Heinrichs Clemens, Marme Frederik, Hartmann Arndt, Loibl Sibylle
Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Bekes I, Janni W, Lato K, Kiechle M, Huober J, Dannecker C, Forstbauer H, Rack B, Harbeck N, Friedl T, Singer S, Eichler M, Fink V. Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. Clin Breast Cancer 2020; 20:439-447.
Apr 6, 2020Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial
Apr 6, 2020Clin Breast Cancer 2020; 20:439-447
Bekes Inga, Janni Wolfgang, Lato Krisztian, Kiechle Marion, Huober Jens, Dannecker Christian, Forstbauer Helmut, Rack Brigitte, Harbeck Nadia, Friedl Thomas W P, Singer Susanne, Eichler Martin, Fink Visnja
Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Schwentner L, Janni W, Kiechle M, Härtl K, Weissenbacher T, Friedl T, Huober J, Scholz C, Wischnik A, Forstbauer H, Rack B, Eichler M, Singer S, Harbeck N, Fink V. Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial. Breast 2016; 27:69-77.
Apr 4, 2016Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trial
Apr 4, 2016Breast 2016; 27:69-77
Schwentner Lukas, Janni Wolfgang, Kiechle Marion, Härtl Kristin, Weissenbacher Tobias, Friedl Thomas W P, Huober Jens, Scholz Christoph, Wischnik Arthur, Forstbauer Helmut, Rack Brigitte, Eichler Martin, Singer Susanne, Harbeck Nadia, Fink Visnja
Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
Erber R, Möbus V, Augustin D, Thomssen C, Jänicke F, Kiechle M, Kuhn W, Nitz U, Harbeck N, Liedtke C, Moustafa Z, Gluz O, Brünner N, Kreipe H, Pelz E, Kates R, Bartels A, Huober J, Mohrmann S, Hartmann A. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial. Breast Cancer Res Treat 2015; 150:279-88.
Feb 28, 2015Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial
Feb 28, 2015Breast Cancer Res Treat 2015; 150:279-88
Erber Ramona, Möbus Volker, Augustin Doris, Thomssen Christoph, Jänicke Fritz, Kiechle Marion, Kuhn Walther, Nitz Ulrike, Harbeck Nadia, Liedtke Cornelia, Moustafa Zehra, Gluz Oleg, Brünner Nils, Kreipe Hans Heinrich, Pelz Enrico, Kates Ronald, Bartels Annette, Huober Jens, Mohrmann Svjetlana, Hartmann Arndt